Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teplizumab versus placebo in recently diagnosed stage 3 type 1 diabetes
NL-OMON59144Phase 3Recruiting
- Sponsor
- Sanofi
- Start
- May 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in diabetes mellitus type 1 (T1D) comparing Teplizumab with Placebo (2 arms). Started May 2026; status: recruiting.
02
Drugs
teplizumab
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on NL-OMON59144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59144.